Page last updated: 2024-11-08

alanine and Central Nervous System Diseases

alanine has been researched along with Central Nervous System Diseases in 3 studies

Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.

Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (66.67)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hermansson, L	1
Yilmaz, A	1
Price, RW	1
Nilsson, S	1
McCallister, S	1
Makadzange, T	1
Das, M	1
Zetterberg, H	1
Blennow, K	1
Gisslen, M	1
Israels, S	1
Haworth, JC	1
Dunn, HG	1
Applegarth, DA	1
Rostain, JC	1
Wardley-Smith, B	1
Forni, C	1
Halsey, MJ	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects[NCT01815736]			Phase 3	1,443 participants (Actual)	Interventional	2013-03-27	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 96

Intervention	percentage of participants (Number)
E/C/F/TAF	90.6
Stay on Baseline Treatment Regimen (SBR)	85.3

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 96

Intervention	percentage of participants (Number)
E/C/F/TAF	92.8
Stay on Baseline Treatment Regimen (SBR)	89.1

Change From Baseline in CD4 Cell Count at Weeks 96

The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen. (NCT01815736)
Timeframe: Baseline; Week 96

Intervention	cells/uL (Mean)
	Baseline	Change at Week 96
E/C/F/TAF	701	60
Stay on Baseline Treatment Regimen (SBR)	689	42

Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48

Intervention	cells/uL (Mean)
	Baseline (NDA Data Cut)	Change at Week 48 (NDA Data Cut)	Baseline (All Participants)	Change at Week 48 (All Participants)
E/C/F/TAF	712	33	701	35
Stay on Baseline Treatment Regimen (SBR)	690	27	689	24

Change From Baseline in Serum Creatinine at Week 48

(NCT01815736)
Timeframe: Baseline; Week 48

Intervention	mg/dL (Mean)
	NDA Data Cut	All Participants
E/C/F/TAF	-0.01	0.00
Stay on Baseline Treatment Regimen (SBR)	0.04	0.03

Change From Baseline in the Overall EFV-related Symptom Assessment Score at Week 48

"The mean (SD) change of the overall EFV-related symptom assessment score is presented. The overall symptom score (ranging from 0 to 20) is the sum of the individual symptom scores ranging from 0 (no symptoms) to 4 (most severe symptoms) from the 5 EFV-related symptom assessments (dizziness, trouble sleeping, impaired concentration, sleepiness, and abnormal or vivid dream). A negative change from baseline indicates improvement.~EFV-Related Symptom Analysis Set: participants who received EFV/FTC/TDF as prior treatment, received at least 1 dose of study drug, and completed EFV-related symptom assessments at the baseline visit and at least 1 postbaseline visit." (NCT01815736)
Timeframe: Baseline; Week 48

Intervention	units on a scale (Mean)
	NDA Data Cut	All Participants
E/C/F/TAF	-1.6	-1.5
Stay on Baseline Treatment Regimen (SBR)	-0.1	-0.1

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. BMD is calculated as grams per square centimeter (g/cm^2); the mean (SD) percentage change is presented. (NCT01815736)
Timeframe: Baseline; Week 48

Intervention	percentage change (Mean)
	NDA Data Cut	All Participants
E/C/F/TAF	1.949	1.468
Stay on Baseline Treatment Regimen (SBR)	-0.136	-0.340

Percent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan. BMD is calculated as g/cm^2; the mean (SD) percentage change is presented. (NCT01815736)
Timeframe: Baseline; Week 48

Intervention	percentage change (Mean)
	NDA Data Cut	All Participants
E/C/F/TAF	1.861	1.557
Stay on Baseline Treatment Regimen (SBR)	-0.110	-0.443

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 48

Intervention	percentage of participants (Number)
	NDA Data Cut	All Participants
E/C/F/TAF	92.2	93.5
Stay on Baseline Treatment Regimen (SBR)	90.4	90.4

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 48

Intervention	percentage of participants (Number)
	NDA Data Cut	All Participants
E/C/F/TAF	95.6	97.2
Stay on Baseline Treatment Regimen (SBR)	92.9	93.1

Reviews

1 review available for alanine and Central Nervous System Diseases

Article	Year
Lactic acidosis in childhood. Advances in pediatrics, 1976, Volume: 22 Topics: Acidosis; Alanine; Autopsy; Brain; Brain Diseases; Central Nervous System Diseases; Child; Child, Pr	1976

Trials

1 trial available for alanine and Central Nervous System Diseases

Article	Year
Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. PloS one, 2019, Volume: 14, Issue:12 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Central Nervous System Diseases; Creatinine; Drug Administ	2019

Other Studies

1 other study available for alanine and Central Nervous System Diseases

Article	Year
Gamma-aminobutyric acid and the high pressure neurological syndrome. Neuropharmacology, 1986, Volume: 25, Issue:5 Topics: Alanine; Aminobutyrates; Animals; Atmospheric Pressure; Central Nervous System Diseases; Electrodes,	1986